Skip to main content
SpringerLink
Log in

Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U (2013) Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798–805. https://doi.org/10.1111/bjh.12210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, Kanamori H, Murata M, Sakura T, Imamura M, Adachi S, Suzuki R, Morishima Y, Sakamaki H, Group PCS (2013) Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant 19(7):1026–1032. https://doi.org/10.1016/j.bbmt.2013.04.004

    Article  PubMed  Google Scholar 

  3. Gmur JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, Metaxas M (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 75(1):290–295

    CAS  PubMed  Google Scholar 

  4. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW (2001) Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 98(6):1687–1694

    Article  CAS  PubMed  Google Scholar 

  5. Olivieri NF (1999) The beta-thalassemias. N Engl J Med 341(2):99–109. https://doi.org/10.1056/NEJM199907083410207

    Article  CAS  PubMed  Google Scholar 

  6. Porter JB (2001) Practical management of iron overload. Br J Haematol 115(2):239–252

    Article  CAS  PubMed  Google Scholar 

  7. Vallejo C, Batlle M, Vazquez L, Solano C, Sampol A, Duarte R, Hernandez D, Lopez J, Rovira M, Jimenez S, Valcarcel D, Belloch V, Jimenez M, Jarque I, Subcommittee of Non-Infectious Complications of the Grupo Espanol de Trasplante H (2014) Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica 99(10):1632–1637. https://doi.org/10.3324/haematol.2014.105908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kroger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK (2016) Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 51(1):89–95. https://doi.org/10.1038/bmt.2015.204

    Article  CAS  PubMed  Google Scholar 

  9. Majhail NS, Lazarus HM, Burns LJ (2010) A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 16(6):832–837. https://doi.org/10.1016/j.bbmt.2010.01.004

    Article  CAS  PubMed  Google Scholar 

  10. Vichinsky E (2008) Clinical application of deferasirox: practical patient management. Am J Hematol 83(5):398–402. https://doi.org/10.1002/ajh.21119

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank all participating clinical hematologists and staff in the Kanto Study Group for Cell Therapy (KSGCT).

Author information

Authors and Affiliations

  1. Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

    Ryo Shimizu, Masahiro Takeuchi, Emiko Sakaida, Chikako Ohwada & Chiaki Nakaseko

  2. Department of Hematology, Asahi General Hospital, Asahi, Japan

    Ryo Shimizu

  3. Department of Hematology and Oncology, School of Medicine, Tokai University, Isehara, Japan

    Masako Toyosaki, Shinichiro Machida & Makoto Onizuka

  4. Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan

    Katsuhiro Shono & Masahiro Onoda

  5. Division of Clinical Oncology and Hematology, Jikei University School of Medicine, Tokyo, Japan

    Takeshi Saito & Shingo Yano

  6. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    Masatsugu Tanaka & Shin Fujisawa

  7. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    Masatsugu Tanaka & Heiwa Kanamori

  8. Division of Hematology, Department of Medicine, School of Medicine, Keio University, Tokyo, Japan

    Takehiko Mori & Shinichiro Okamoto

  9. Department of Hematology, NTT Medical Center, Tokyo, Japan

    Kensuke Usuki

  10. Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Satoshi Takahashi

  11. Department of Hematology, School of Medicine, International University of Health and Welfare, Narita, Japan

    Chiaki Nakaseko

Authors
  1. Ryo Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emiko Sakaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chikako Ohwada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masako Toyosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinichiro Machida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Makoto Onizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuhiro Shono
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shingo Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masatsugu Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shin Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takehiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kensuke Usuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Satoshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Heiwa Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Chiaki Nakaseko
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.S, M.T., and C.N. designed the research. R.S. and M.T. collected and analyzed patients’ clinical data and performed statistical analysis. R.S., M.T., E.S., C.O., M.T., S.M., M.O., K.S., M.O., T.S., S.Y., M.T. S.F., T.M., K.U., S.T., H.K., C.N., and S.O. were responsible for patient care and stem cell transplantation. R.S., M.T., E.S., and C.N. wrote the manuscript. All authors reviewed the draft manuscript and approved the final version of the manuscript for submission.

Corresponding author

Correspondence to Masahiro Takeuchi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the ethical committee of the Graduate School of Medicine, Chiba University, Chiba, Japan (accession no. 564). This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained in the form of opt-out on the website.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimizu, R., Takeuchi, M., Sakaida, E. et al. Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Ann Hematol 98, 1781–1783 (2019). https://doi.org/10.1007/s00277-019-03717-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03717-8

Search

Navigation